The Ongoing Saga of the Evolution of Percutaneous Coronary Intervention: From Balloon Angioplasty to Recent Innovations to Future Prospects.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
10 2022
Historique:
received: 03 03 2022
revised: 20 06 2022
accepted: 21 06 2022
pubmed: 2 7 2022
medline: 13 10 2022
entrez: 1 7 2022
Statut: ppublish

Résumé

The advances in percutaneous coronary intervention (PCI) have been, above all, dependent on the work of pioneers in surgery, radiology, and interventional cardiology. From Grüntzig's first balloon angioplasty, PCI has expanded through technology development, improved protocols, and dissemination of best-practice techniques. We can nowadays treat more complex lesions in higher-risk patients with favourable results. Guide wires, balloon types and profiles, debulking techniques such as atherectomy or lithotripsy, stents, and scaffolds all represent evolutions that have allowed us to tackle complex lesions such as an unprotected left main coronary artery, complex bifurcations, or chronic total occlusions. Best-practice PCI, including physiology assessment, imaging, and optimal lesion preparation are now the gold standard when performing PCI for sound indications, and new technologies such as intravascular lithotripsy for lesion preparation, or artificial intelligence, are innovations in the steps of 4 decades of pioneers to improve patient care in interventional cardiology. In the present review, major innovations in PCI since the first balloon angioplasty and also uncertainties and obstacles inherent to such medical advances are described.

Identifiants

pubmed: 35777682
pii: S0828-282X(22)00399-3
doi: 10.1016/j.cjca.2022.06.019
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S30-S41

Informations de copyright

Copyright © 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Fabien Picard (F)

Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France. Electronic address: fabien.picard@live.fr.

Michele Pighi (M)

Department of Medicine, University of Verona, Verona, Italy.

Guillaume Marquis-Gravel (G)

Interventional Cardiology, Department of Medicine, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.

Marino Labinaz (M)

Ottawa University Heart Institute, Ottawa, Ontario, Canada.

Eric A Cohen (EA)

Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Jean-François Tanguay (JF)

Interventional Cardiology, Department of Medicine, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH